BioSpace News Archive

US Medical Innovations, LLC (USMI), a Biomedical and Life Science subsidiary of US Patent Innovations, LLC, announced today it has received FDA Approval for its Canady Flex RoboWrist™ to be used in open and laparoscopic procedures in the United States.

NanoTemper Technologies, creator of biophysical tools for drug discovery, proudly announced the launch of their highly anticipated Biotinylated Target Labeling Kit, expanding the molecular interaction analysis toolkit for scientists working with complex or undruggable targets, filling a vital gap in screening and hit validation workflows in the pharma industry.

Inhibikase Therapeutics, Inc. today announced that it will effect a 1-for-6 reverse stock split of its common stock.

City of Hope announced that effective June 30, David W. Craig, Ph.D., will be professor and founding chair of its newly created Department of Integrative Translational Sciences within Beckman Research Institute of City of Hope.

Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus” or the “Company”) announces that its shareholders have approved all proposals by the Board of Directors at the 2023 Annual General Meeting (“AGM”), held yesterday at the Radisson Blu Hotel Basel, Steinentorstrasse 25, 4051 Basel, Switzerland.

AlloSource® announced the Journal of Orthopaedic Surgery published the study titled “Short term clinical outcomes of a ProChondrix® thin laser-etched osteochondral allograft for the treatment of articular cartilage defects in the knee.” This study demonstrated encouraging patient-reported outcomes in the treatment of symptomatic articular cartilage lesions using a laser-etched osteochondral allograft, ProChondrix.

Moderna, Inc. (NASDAQ: MRNA) today announced that it has initiated the filing of a rolling New Drug Submission (NDS) to Health Canada for its updated monovalent COVID-19 vaccine, SPIKEVAX® XBB.1.5 (mRNA-1273.815) targeting the omicron subvariant XBB.1.5 of SARS-CoV-2.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”) today announced the publication of positive data from its Phase 1/2 clinical trial, which demonstrated promising safety and efficacy results for Trappsol® Cyclo™ in the treatment of Niemann-Pick Disease Type C1, a rare, genetic disease causing cholesterol accumulation in cells, leading to dysfunction of the liver, lung, spleen and brain and premature death.

AACC is pleased to announce that the journal Clinical Chemistry received an impact factor of 9.3 —the second highest in the journal’s history—and the Journal of Applied Laboratory Medicine received its first impact factor, of 2.0, according to the newly released 2022 Clarivate Journal Citation Reports.

Liberation Labs, broke ground on its first commercial-scale, purpose-built, precision fermentation biomanufacturing facility in Richmond, Indiana.